Latest Breaking News On - எங்களுக்கு தேசிய புற்றுநோய் நிறுவனம் - Page 13 : comparemela.com

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent 1 A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer Merck is leading more than ten clinical trials across DNA Damage Response (DDR) pathways in various tumor types Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide.

United statesDanish thomasJulissa vianaNational cancer instituteLasker clinical research scholarCancer researchMerck kgaDevelopmental therapeutics branchAmerican cancer societyVertex pharmaceuticalsDevelopment agreementNational institutes of healthMerck pressAmerican cancer society small cell lungUs national cancer instituteGlobal head of development for the healthcare